Drug – bio-affecting and body treating compositions – Lymphokine
Patent
1988-08-26
1992-10-20
Doll, John
Drug, bio-affecting and body treating compositions
Lymphokine
514 21, A61K 3900, A61K 3702
Patent
active
051568411
ABSTRACT:
An antitumor vaccine utilizing oncoproteins as immunogen is disclosed. The oncoprotein could be administered either as isolated, substantially pure product or expressed through a recombinant vaccinia virus containing either the complete coding sequence for the oncoprotein(s) or portions thereof.
REFERENCES:
patent: 4701442 (1987-10-01), Revici
patent: 4720386 (1988-01-01), McCollester
Chang et al., Relationship Between T-Antigen and Tumor-Specific Transplantation Antigen in Simian Virus 40-Transformed Cells, Journal of Virology, vol. 29, No. 1, pp. 69-74, 1979.
Hanahan, Heritable Formation of Pancreatic B-Cell Tumours in Transgenic Mice Expressing Recombinant Insulin/Simian Virus 40 Oncogenes Nature, vol. 315, pp. 115-122, issue of May 9, 1985.
Watt et al., "Expression and Characterization of the Human C-Myc DNA-Biding Protein", Mol. Cell. Biol. 5: 448-456 (1985).
Tevethia et al., "Biology of Simian Virus 40 (SU40) Transplantation Antigen (TrAg)", Virol. 107: 13-23 (1980).
George E. Mark and Ulf R. Rapp, "Primary Structure of V-Raf: Relatedness to the SRC Family of Oncogenes", Science (1984) 224:285-289.
P. Sutrave et al., "Nucleotide Sequence of Avian Retroviral Oncogene V-Mil: Homologue of Murine Retroviral Oncogene V-Raf", Nature (1984) 309:85-88.
Doll John
Elliott George C.
United States of America
LandOfFree
Anti-tumor vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-tumor vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-tumor vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-190624